Opioids, Abortion, And Drug Advertising: How A Califf-Led FDA Might Address Hot Button Rx Topics
Executive Summary
Robert Califf offers some interesting clues as to how he’d handle top drug policy issues in his Senate confirmation hearing.
You may also be interested in...
US FDA Looking For Senior Leader In New Drugs Office To Oversee Substance Use Disorder Issues
The deputy Office of New Drugs director will have decision-making authority and help shape policy for substance use efforts.
FDA Exploring Partnerships As Alternative To REMS Mandate For Opioid Education
The US FDA is continuing to think through mechanisms to make opioid prescriber education mandatory – either separate from or in addition to relying on its REMS authority.
Califf Says Opioid Labeling Changes, Withdrawals Still Possible
The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.